Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 39
Filter
1.
J Artif Organs ; 20(4): 381-385, 2017 Dec.
Article in English | MEDLINE | ID: mdl-28391521

ABSTRACT

The purpose of this study was to evaluate the effects of sinusoidal pump speed modulation of the Cleveland Clinic continuous-flow total artificial heart (CFTAH) on hemodynamics and pump flow in an awake chronic calf model. The sinusoidal pump speed modulations, performed on the day of elective sacrifice, were set at ±15 and ± 25% of mean pump speed at 80 bpm in four awake calves with a CFTAH. The systemic and pulmonary arterial pulse pressures increased to 12.0 and 12.3 mmHg (±15% modulation) and to 15.9 and 15.7 mmHg (±25% modulation), respectively. The pulsatility index and surplus hemodynamic energy significantly increased, respectively, to 1.05 and 1346 ergs/cm at ±15% speed modulation and to 1.51 and 3381 ergs/cm at ±25% speed modulation. This study showed that it is feasible to generate pressure pulsatility with pump speed modulation; the platform is suitable for evaluating the physiologic impact of pulsatility and allows determination of the best speed modulations in terms of magnitude, frequency, and profiles.


Subject(s)
Heart, Artificial , Pulsatile Flow , Animals , Cattle , Heart-Assist Devices , Hemodynamics
2.
Artif Organs ; 41(5): 411-417, 2017 May.
Article in English | MEDLINE | ID: mdl-27401215

ABSTRACT

Cleveland Clinic's continuous-flow total artificial heart (CFTAH) provides systemic and pulmonary circulations using one assembly (one motor, two impellers). The right pump hydraulic output to the pulmonary circulation is self-regulated by the rotating assembly's passive axial movement in response to atrial differential pressure to balance itself to the left pump output. This combination of features integrates a biocompatible, pressure-balancing regulator with a double-ended pump. The CFTAH requires no flow or pressure sensors. The only control parameter is pump speed, modulated at programmable rates (60-120 beats/min) and amplitudes (0 to ±25%) to provide flow pulses. In bench studies, passive self-regulation (range: -5 mm Hg ≤ [left atrial pressure - right atrial pressure] ≤ 10 mm Hg) was demonstrated over a systemic/vascular resistance ratio range of 2.0-20 and a flow range of 3-9 L/min. Performance of the most recent pump configuration was demonstrated in chronic studies, including three consecutive long-term experiments (30, 90, and 90 days). These experiments were performed at a constant postoperative mean speed with a ±15% speed modulation, demonstrating a totally self-regulating mode of operation, from 3 days after implant to explant, despite a weight gain of up to 40%. The mechanism of self-regulation functioned properly, continuously throughout the chronic in vivo experiments, demonstrating the performance goals.


Subject(s)
Heart, Artificial , Animals , Blood Pressure , Cattle , Hemodynamics , Prosthesis Design , Prosthesis Implantation , Pulsatile Flow , Vascular Resistance
3.
Artif Organs ; 41(6): 568-572, 2017 Jun.
Article in English | MEDLINE | ID: mdl-27654489

ABSTRACT

The unique device architecture of the Cleveland Clinic continuous-flow total artificial heart (CFTAH) requires dedicated and specific air-removal techniques during device implantation in vivo. These procedures comprise special surgical techniques and intraoperative manipulations, as well as engineering design changes and optimizations to the device itself. The current study evaluated the optimal air-removal techniques during the Cleveland Clinic double-ended centrifugal CFTAH in vivo implants (n = 17). Techniques and pump design iterations consisted of developing a priming method for the device and the use of built-in deairing ports in the early cases (n = 5). In the remaining cases (n = 12), deairing ports were not used. Dedicated air-removal ports were not considered an essential design requirement, and such ports may represent an additional risk for pump thrombosis. Careful passive deairing was found to be an effective measure with a centrifugal pump of this design. In this report, the techniques and design changes that were made during this CFTAH development program to enable effective residual air removal and prevention of air embolism during in vivo device implantation are explained.


Subject(s)
Cardiac Surgical Procedures/methods , Heart, Artificial , Prosthesis Implantation/methods , Animals , Cardiac Surgical Procedures/adverse effects , Cattle , Embolism, Air/etiology , Embolism, Air/prevention & control , Heart, Artificial/adverse effects , Prosthesis Design , Prosthesis Implantation/adverse effects , Thrombosis/etiology , Thrombosis/prevention & control
4.
Artif Organs ; 41(5): 476-481, 2017 May.
Article in English | MEDLINE | ID: mdl-27878837

ABSTRACT

The development of total artificial heart devices is a complex undertaking that includes chronic biocompatibility assessment of the device. It is considered particularly important to assess whether device design and features can be compatible long term in a biological environment. As part of the development program for the Cleveland Clinic continuous-flow total artificial heart (CFTAH), we evaluated the device for signs of thrombosis and biological material deposition in four animals that had achieved the intended 14-, 30-, or 90-day durations in each respective experiment. Explanted CFTAHs were analyzed for possible clot buildup at "susceptible" areas inside the pump, particularly the right pump impeller. Depositions of various consistency and shapes were observed. We here report our findings, along with macroscopic and microscopic analysis post explant, and provide computational fluid dynamics data with its potential implications for thrombus formation.


Subject(s)
Heart, Artificial/adverse effects , Thrombosis/etiology , Animals , Cattle , Hydrodynamics , Prosthesis Design , Prosthesis Implantation/adverse effects , Thrombosis/pathology
5.
Artif Organs ; 40(10): 1022-1027, 2016 Oct.
Article in English | MEDLINE | ID: mdl-26684685

ABSTRACT

The choice of optimal operative access technique for mechanical circulatory support device implantation ensures successful postoperative outcomes. In this study, we retrospectively evaluated the median sternotomy and lateral thoracotomy incisions for placement of the Cleveland Clinic continuous-flow total artificial heart (CFTAH) in a bovine model. The CFTAH was implanted in 17 calves (Jersey calves; weight range, 77.0-93.9 kg) through a median sternotomy (n = 9) or right thoracotomy (n = 8) for elective chronic implantation periods of 14, 30, or 90 days. Similar preoperative preparation, surgical techniques, and postoperative care were employed. Implantation of the CFTAH was successfully performed in all cases. Both methods provided excellent surgical field visualization. After device connection, however, the median sternotomy approach provided better visualization of the anastomoses and surgical lines for hemostasis confirmation and repair due to easier device displacement, which is severely limited following right thoracotomy. All four animals sacrificed after completion of the planned durations (up to 90 days) were operated through full median sternotomy. Our data demonstrate that both approaches provide excellent initial field visualization. Full median sternotomy provides larger viewing angles at the anastomotic suture line after device connection to inflow and outflow ports.


Subject(s)
Heart, Artificial , Sternotomy/methods , Thoracotomy/methods , Animals , Cattle , Female , Male , Postoperative Care , Retrospective Studies
6.
Int J Artif Organs ; 38(8): 465-7, 2015 Aug.
Article in English | MEDLINE | ID: mdl-26349531

ABSTRACT

In vivo preclinical testing of mechanical circulatory devices requires large animal models that provide reliable physiological and hemodynamic conditions by which to test the device and investigate design and development strategies. Large bovine species are commonly used for mechanical circulatory support device research. The animals used for chronic in vivo support require high-quality care and excellent surgical techniques as well as advanced methods of postoperative care. These techniques are constantly being updated and new methods are emerging.We report results of our double steel-wire closure technique in large bovine models used for Cleveland Clinic's continuous-flow total artificial heart development program. This is the first report of double-wire sternal fixation used in large bovine models.


Subject(s)
Heart, Artificial , Sternum/surgery , Suture Techniques , Animals , Cattle , Models, Animal , Sternotomy
7.
J Thorac Cardiovasc Surg ; 150(3): 687-93.e1, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26173607

ABSTRACT

OBJECTIVE: The Cleveland Clinic continuous-flow total artificial heart (CFTAH) is a compact, single-piece, valveless, pulsatile pump providing self-regulated hemodynamic output to left/right circulation. We evaluated chronic in vivo pump performance, physiologic and hemodynamic parameters, and biocompatibility of the CFTAH in a well-established calf model. METHODS: CFTAH pumps have been implanted in 17 calves total. Hemodynamic parameters, pump performance, and device-related adverse events were evaluated during studies and at necropsy. RESULTS: In vivo experiments demonstrated good hemodynamic performance (pump flow, 7.3 ± 0.7 L/min; left atrial pressure, 16 ± 3 mm Hg; right atrial pressure, 17 ± 3 mm Hg; right atrial pressure-left atrial pressure difference, 1 ± 2 mm Hg; mean arterial pressure, 103 ± 7 mm Hg; arterial pulse pressure, 30 ± 11 mm Hg; and pulmonary arterial pressure, 34 ± 5 mm Hg). The CFTAH has operated within design specifications and never failed. With ever-improving pump design, the implants have shown no chronic hemolysis. Three animals with recent CFTAH implantation recovered well, with no postoperative anticoagulation, during planned in vivo durations of 30, 90, and 90 days (last 2 were intended to be 90-day studies). All these longest-surviving cases showed good biocompatibility, with no thromboembolism in organs. CONCLUSIONS: The current CFTAH has demonstrated reliable self-regulation of hemodynamic output and acceptable biocompatibility without anticoagulation throughout 90 days of chronic implantation in calves. Meeting these milestones is in accord with our strategy to achieve transfer of this unique technology to human surgical practice, thus filling the urgent need for cardiac replacement devices as destination therapy.


Subject(s)
Biocompatible Materials , Blood Circulation , Cardiac Surgical Procedures/instrumentation , Heart, Artificial , Hemodynamics , Prosthesis Implantation/instrumentation , Animals , Arterial Pressure , Atrial Function, Left , Atrial Function, Right , Atrial Pressure , Cattle , Models, Animal , Prosthesis Design , Pulsatile Flow , Time Factors
8.
ASAIO J ; 61(6): 726-8, 2015.
Article in English | MEDLINE | ID: mdl-26102177

ABSTRACT

The Cleveland Clinic continuous-flow total artificial heart passively regulates itself in regard to the relative performance of systemic and pulmonary pumps. The system incorporates real-time monitoring to detect any indication of incipient left or right suction as input for automatic controller response. To recognize suction, the external controller compares the waveforms of modulating speed input and power feedback. Deviations in periodic waveforms indicate sudden changes to flow impedance, which are characteristic of suction events as the pump speed is modulating. Incipient suction is indicated within 3 seconds of being detected in the power wave form, allowing timely controller response before mean flow is affected. This article describes the results obtained from subjecting the system to severe hemodynamic manipulation during an acute study in a calf.


Subject(s)
Heart, Artificial , Algorithms , Animals , Cattle , Equipment Design , Hemodynamics , Suction
9.
J Artif Organs ; 18(4): 358-60, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26105105

ABSTRACT

The biocompatibility assessment of the Cleveland Clinic continuous-flow total artificial heart is an important part of the device developmental program. Surgical and postoperative management are key factors in achieving optimal outcomes. However, the presence of vascular anatomical abnormalities in experimental animal models is often unpredictable and may worsen the expected outcomes. We report a technical impediment encountered during total artificial heart implantation complicated by unfavorable bovine anatomy of the ascending aorta and brachiocephalic arterial trunk.


Subject(s)
Aorta/anatomy & histology , Aorta/surgery , Brachiocephalic Trunk/anatomy & histology , Brachiocephalic Trunk/surgery , Heart, Artificial , Prosthesis Implantation , Animals , Cattle , Models, Animal
10.
J Artif Organs ; 18(4): 354-7, 2015 Dec.
Article in English | MEDLINE | ID: mdl-25939428

ABSTRACT

Post-explant evaluation of the continuous-flow total artificial heart in preclinical studies can be extremely challenging because of the device's unique architecture. Determining the exact location of tissue regeneration, neointima formation, and thrombus is particularly important. In this report, we describe our first successful experience with visualizing the Cleveland Clinic continuous-flow total artificial heart using a custom-made high-definition miniature camera.


Subject(s)
Heart, Artificial , Thrombosis/etiology , Thrombosis/pathology , Animals , Cattle , Male , Materials Testing
11.
ASAIO J ; 61(4): 424-8, 2015.
Article in English | MEDLINE | ID: mdl-25806613

ABSTRACT

Implantation of mechanical circulatory support devices is challenging, especially in patients with a small chest cavity. We evaluated how well the Cleveland Clinic continuous-flow total artificial heart (CFTAH) fit the anatomy of patients about to receive a heart transplant. A mock pump model of the CFTAH was rapid-prototyped using biocompatible materials. The model was brought to the operative table, and the direction, length, and angulation of the inflow/outflow ports and outflow conduits were evaluated after the recipient's ventricles had been resected. Thoracic cavity measurements were based on preoperative computed tomographic data. The CFTAH fit well in all five patients (height, 170 ± 9 cm; weight, 75 ± 24 kg). Body surface area was 1.9 ± 0.3 m (range, 1.6-2.1 m). The required inflow and outflow port orientation of both the left and right housings appeared consistent with the current version of the CFTAH implanted in calves. The left outflow conduit remained straight, but the right outflow direction necessitated a 73 ± 22 degree angulation to prevent potential kinking when crossing over the connected left outflow. These data support the fact that our design achieves the proper anatomical relationship of the CFTAH to a patient's native vessels.


Subject(s)
Body Size , Heart-Assist Devices , Models, Anatomic , Thoracic Cavity/anatomy & histology , Equipment Design , Female , Heart Failure/surgery , Humans , Imaging, Three-Dimensional , Male , Middle Aged
12.
Ann Thorac Surg ; 96(1): 148-54, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23731607

ABSTRACT

BACKGROUND: We previously reported renal arterial periarteritis after implantation of a continuous-flow left ventricular assist device in calves. The purpose of the present study was to investigate whether the same periarteritis changes occur in the intrapulmonary arteries after implantation of a continuous-flow right ventricular assist device (CFRVAD) in calves and to determine the mechanism of those histologic changes. METHODS: Ten calves were implanted with a CFRVAD for 29 ± 7 days, and we compared pulmonary artery samples and hemodynamic data before and after CFRVAD implantation prospectively. RESULTS: After implantation, the pulsatility index (pulmonary arterial pulse pressure/pulmonary arterial mean pressure) significantly decreased (0.88 ± 0.40 before vs 0.51 ± 0.22 after; p < 0.05), with severe periarteritis of the intrapulmonary arteries in all animals. Periarterial pathology included hyperplasia and inflammatory cell infiltration. The number of inflammatory cells positive for the angiotensin II type 1 receptor was significantly higher after implantation (7.8 ± 6.5 pre-CFRVAD vs 313.2 ± 145.2 at autopsy; p < 0.01). Serum angiotensin-converting enzyme activity significantly decreased after implantation from 100% to 49.7 ± 17.7% at week 1 (p = 0.01). Tissue levels of angiotensin-converting enzyme also demonstrated a significant reduction (0.381 ± 0.232 before implantation vs 0.123 ± 0.096 at autopsy; p = 0.043). CONCLUSIONS: Periarteritis occurred in the intrapulmonary arteries of calves after CFRVAD implantation. The local renin-angiotensin system (not the angiotensin-converting enzyme pathway) plays an important role in such changes.


Subject(s)
Arteritis/pathology , Heart Failure/surgery , Heart-Assist Devices/adverse effects , Lung/blood supply , Pulmonary Artery , Renin-Angiotensin System/physiology , Animals , Arteritis/etiology , Arteritis/metabolism , Blotting, Western , Cattle , Disease Models, Animal , Heart Failure/metabolism , Heart Failure/physiopathology , Hemodynamics , Immunohistochemistry , Male , Peptidyl-Dipeptidase A/metabolism , Receptor, Angiotensin, Type 1/metabolism
13.
Ann Thorac Surg ; 95(1): 373-80, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23272869

ABSTRACT

With implantable cardiac assist devices increasingly proving their effectiveness as therapeutic options for end-stage heart failure, it is important for clinicians to understand the unique physiology of device-assisted circulation. Preload sensitivity as it relates to cardiac assist devices is derived from the Frank-Starling relationship between human ventricular filling pressures and ventricular stroke volume. In this review, we stratify the preload sensitivity of 17 implantable cardiac assist devices relative to the native heart and discuss the effect of preload sensitivity on left ventricular volume unloading, levels of cardiac support, and the future development of continuous-flow total artificial heart technology.


Subject(s)
Heart Failure/surgery , Heart-Assist Devices/standards , Ventricular Pressure/physiology , Equipment Design , Heart Failure/physiopathology , Humans
14.
Artif Organs ; 37(2): 121-7, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23043450

ABSTRACT

The aim of this study was to evaluate the safety and performance of the Arrow CorAide left ventricular assist system (LVAS) (Arrow International, Reading, PA, USA), a continuous-flow left ventricular assist device, as bridge to transplantation or recovery as well as destination therapy in patients with New York Heart Association (NYHA) class IV heart failure. Twenty-one patients were implanted with the CorAide LVAS between February 2005 and February 2006 in a prospective, multicenter, nonrandomized trial. Seventeen patients (81%) survived to >180 days or to transplantation. The cumulative time on device was 16.58 patient years (range 23-796 days, median 192 days). No intraoperative technical issues were observed at the time of implantation. Of the 21 implants, nine patients died on device, two were converted to other devices, and 10 were transplanted. Three patient deaths were attributed to pump polymer coating delamination. Postmortem device inspection determined delamination of the polymer coating on the pump's internal surface to be the cause of the late hemolysis and sudden fatal pump stops. No embolic or driveline infection event was recorded. The automatic flow control algorithm functioned reliably throughout the trial. Primary performance trial endpoint was achieved with 81% survival to 180 days or transplantation. Delamination of the polymer coating on the internal surface of the pump with resultant hemolysis and pump stops was the sole major device event in this trial. Elimination of the polymer coating and replacement with an amorphous carbon coating has resolved this in preclinical testing, prior to initiation of further clinical testing of this device.


Subject(s)
Coated Materials, Biocompatible , Heart Failure/therapy , Heart-Assist Devices , Polymers , Ventricular Function, Left , Aged , Europe , Female , Heart Failure/diagnosis , Heart Failure/mortality , Heart Failure/physiopathology , Heart Transplantation , Heart-Assist Devices/adverse effects , Hemolysis , Humans , Male , Middle Aged , Prospective Studies , Prosthesis Design , Prosthesis Failure , Time Factors , Treatment Outcome
15.
Artif Organs ; 36(8): 705-13, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22747979

ABSTRACT

Cleveland Clinic's continuous-flow total artificial heart has one motor and one rotating assembly supported by a hydrodynamic bearing. The right hydraulic output is self regulated by passive axial movement of the rotating assembly to balance itself with the left output. The purpose of this article is to present progress in four areas of development: the automatic speed control system, self-regulation to balance right/left inlet pressures and flows, hemolysis testing using calf blood, and coupled electromagnetics (EMAG) and computational fluid dynamics (CFD) analysis. The relationships between functions of motor power and speed, systemic flow, and systemic vascular resistance (SVR) were used for the sensorless speed control algorithm and demonstrated close correlations. Based on those empirical relationships, systemic flow and SVR were calculated in the system module and showed good correlation with measured pump flow and SVR. The automatic system adjusted the pump's speed to obtain the target flow in response to the calculated SVR. Atrial pressure difference (left minus right atrial pressure) was maintained within ±10 mm Hg for a wide range of SVR/pulmonary vascular resistance ratios, demonstrating a wide margin of self-regulation under fixed-speed mode and 25% sinusoidally modulated speed mode. Hemolysis test results indicated acceptable values (normalized index of hemolysis <0.01 mg/dL). The coupled EMAG/CFD model was validated for use in further device development.


Subject(s)
Heart, Artificial , Algorithms , Animals , Cattle , Equipment Design , Erythrocytes/cytology , Heart, Artificial/adverse effects , Hemolysis , Humans , Hydrodynamics , Models, Cardiovascular
16.
Ann Thorac Surg ; 93(5): 1746-52, 2012 May.
Article in English | MEDLINE | ID: mdl-22459544

ABSTRACT

Although the need for right ventricular assist device (RVAD) support for right ventricular failure after the implantation of a continuous-flow left ventricular assist device has decreased, right ventricular failure still occurs in as many as 44% of patients after continuous-flow left ventricular assist device insertion. Cleveland Clinic's DexAide continuous-flow RVAD was implanted in 34 calves during the course of its development. This review discusses lessons learned in the design and development of an implantable continuous-flow RVAD that are drawn from the results of these in vivo studies, our clinical experience with RVAD support, and a review of previously published reports on clinical RVAD use.


Subject(s)
Equipment Design , Equipment Failure , Heart-Assist Devices , Ventricular Dysfunction, Right/surgery , Animals , Anticoagulants/therapeutic use , Disease Models, Animal , Equipment Safety , Female , Heart Failure/mortality , Heart Failure/physiopathology , Heart Failure/surgery , Humans , Male , Needs Assessment , Ohio , Prognosis , Prosthesis Implantation , Pulsatile Flow/physiology , Risk Assessment , Survival Analysis , Thromboembolism/drug therapy , Thromboembolism/physiopathology , Ventricular Dysfunction, Right/physiopathology
17.
ASAIO J ; 56(5): 403-9, 2010.
Article in English | MEDLINE | ID: mdl-20616704

ABSTRACT

This study demonstrated the concept of using speed modulation in a continuous-flow total artificial heart (CFTAH) to shape arterial pressure waveforms and to adjust pressure pulsatility. A programmable function generator was used to determine the optimum pulsatile speed profile. Three speed profiles [sinusoidal, rectangular, and optimized (a profile optimized for generation of a physiologic arterial pressure waveform)] were evaluated using the CFTAH mock circulatory loop. Hemodynamic parameters were recorded at average pump speeds of 2,700 rpm and a modulation cycle of 60 beats per minute. The effects of varying physiologically relevant vascular resistance and lumped compliance on the hemodynamics were assessed. The feasibility of using speed modulation to manipulate systemic arterial pressure waveforms, including a physiologic pressure waveform, was demonstrated in vitro. The additional pump power consumption needed to generate a physiologic pulsatile pressure was 16.2% of the power consumption in nonpulsatile continuous-flow mode. The induced pressure waveforms and pulse pressure were shown to be very responsive to changes in both systemic vascular resistance and arterial compliance. This system also allowed pulsatile pulmonary arterial waveform. Speed modulation in the CFTAH could enable physicians to obtain desired pressure waveforms by simple manual adjustment of speed control input waveforms.


Subject(s)
Blood Pressure/physiology , Heart, Artificial , Models, Cardiovascular , Prosthesis Design/instrumentation , Pulsatile Flow/physiology
18.
Artif Organs ; 34(12): 1158-63, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20545668

ABSTRACT

The purpose of this study was to evaluate in vivo the biocompatibility of BioMedFlex (BMF), a new resilient, hard-carbon, thin-film coating, as a blood journal bearing material in Cleveland Heart's (Charlotte, NC, USA) continuous-flow right and left ventricular assist devices (RVADs and LVADs). BMF was applied to RVAD rotating assemblies or both rotating and stator assemblies in three chronic bovine studies. In one case, an LVAD with a BMF-coated stator was also implanted. Cases 1 and 3 were electively terminated at 18 and 29 days, respectively, with average measured pump flows of 4.9 L/min (RVAD) in Case 1 and 5.7 L/min (RVAD) plus 5.7 L/min (LVAD) in Case 3. Case 2 was terminated prematurely after 9 days because of sepsis. The sepsis, combined with running the pump at minimum speed (2000 rpm), presented a worst-case biocompatibility challenge. Postexplant evaluation of the blood-contacting journal bearing surfaces showed no biologic deposition in any of the four pumps. Thrombus inside the RVAD inlet cannula in Case 3 is believed to be the origin of a nonadherent thrombus wrapped around one of the primary impeller blades. In conclusion, we demonstrated that BMF coatings can provide good biocompatibility in the journal bearing for ventricular assist devices.


Subject(s)
Carbon/metabolism , Coated Materials, Biocompatible/metabolism , Heart-Assist Devices , Materials Testing , Animals , Carbon/adverse effects , Cattle , Coated Materials, Biocompatible/adverse effects , Hemodynamics , Platelet Aggregation , Prosthesis Implantation
19.
Artif Organs ; 34(6): 512-6, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20482709

ABSTRACT

Zirconia is a ceramic with material properties ideal for journal bearing applications. The purpose of this study was to evaluate the use of zirconium oxide (zirconia) as a blood journal bearing material in the DexAide right ventricular assist device. Zirconia ceramic was used instead of titanium to manufacture the DexAide stator housing without changing the stator geometry or the remaining pump hardware components. Pump hydraulic performance, journal bearing reliability, biocompatibility, and motor efficiency data of the zirconia stator were evaluated in six chronic bovine experiments for 14-91 days and compared with data from chronic experiments using the titanium stator. Pump performance data including average in vivo pump flows and speeds using a zirconia stator showed no statistically significant difference to the average values for 16 prior titanium stator in vivo studies, with the exception of a 19% reduction in power consumption. Indices of hemolysis were comparable for both stator types. Results of coagulation assays and platelet aggregation tests for the zirconia stator implants showed no device-induced increase in platelet activation. Postexplant evaluation of the zirconia journal bearing surfaces showed no biologic deposition in any of the implants. In conclusion, zirconia ceramic can be used as a hemocompatible material to improve motor efficiency while maintaining hydraulic performance in a blood journal bearing application.


Subject(s)
Ceramics/metabolism , Heart-Assist Devices , Zirconium/metabolism , Animals , Blood Coagulation , Cattle , Ceramics/chemistry , Equipment Design , Heart Ventricles/surgery , Hemodynamics , Platelet Aggregation , Zirconium/chemistry
20.
J Heart Lung Transplant ; 29(1): 32-6, 2010 Jan.
Article in English | MEDLINE | ID: mdl-20123244

ABSTRACT

BACKGROUND: Although some continuous-flow left ventricular assist device algorithms have been created to respond to varying patient physiology, very little research has been conducted on control of right ventricular support in uni- or biventricular application. The purpose of this study was to develop and evaluate a simple and reliable fixed-flow algorithm for the DexAide right ventricular assist device (RVAD). This algorithm automatically adjusts speed to maintain a target flow while preventing ventricular suction when a requested target flow exceeds available tricuspid flow. METHODS: Fixed-flow control mode was evaluated in 17 DexAide RVAD long-term bovine studies, with a duration ranging from 14 to 90 days (33 +/- 24 days). Targeted fixed-flow levels ranged from 4.0 to 6.5 liters/min. Data were monitored on an hourly basis. Pump-flow data were also recorded on a weekly basis to document the speed increment required to increase pump flow from 5 to 8 liters/min at 0.5-liter/min increments. RESULTS: The fixed-flow control mode was evaluated for a total duration of 5,283 hours without complications related to pump flow or left/right circulation imbalance. The pump speed varied between 2,000 and 3,220 rpm to maintain the flow constant at each target level. The average absolute mismatch between the target flow and measured flow was 0.6 +/- 0.5 liter/min. CONCLUSIONS: Fixed-flow control mode with a pre-determined maximum automatic pump speed can be used safely and effectively in the DexAide RVAD. It can provide target flows by adjusting the pump speed while monitoring pump-flow response to automatic speed increment requests.


Subject(s)
Algorithms , Blood Circulation/physiology , Heart-Assist Devices , Ventricular Function, Right/physiology , Animals , Cardiac Output/physiology , Cattle , Models, Animal , Pulmonary Circulation/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...